Overview

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

Status:
Not yet recruiting

Trial end date:
2026-07-20

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to investigate efficacy, pharmacokinetics and safety of the drug in pediatric participants with moderately to severely active ulcerative colitis (UC).

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Mirikizumab